This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Spanish Clinical Research Network | |
|---|---|
| Name | Spanish Clinical Research Network |
| Native name | Red Española de Investigación Clínica |
| Formation | 1990s |
| Headquarters | Madrid, Spain |
| Region served | Spain |
| Leader title | Director |
| Parent organization | Instituto de Salud Carlos III |
Spanish Clinical Research Network
The Spanish Clinical Research Network is a national biomedical research initiative headquartered in Madrid that coordinates multicenter clinical trial activity across Spanish autonomous communitys and links to European and global research infrastructures. It supports translational projects involving hospitals such as Hospital Clínic de Barcelona and Hospital Universitario La Paz, research institutes like Centro Nacional de Investigaciones Oncológicas and Centro de Investigaciones Biológicas, and regulatory bodies including the Agencia Española de Medicamentos y Productos Sanitarios and the European Medicines Agency. The network interfaces with funding agencies such as the Instituto de Salud Carlos III, the European Commission, and charitable funders like the Bill & Melinda Gates Foundation and private partners including GlaxoSmithKline and Roche.
The network emerged in the late 20th century amid reforms following initiatives from the Ministerio de Sanidad and the Instituto de Salud Carlos III and aligned with European frameworks like the EU Framework Programme and the European Research Area, building on precedents set by institutions such as Fundación Jiménez Díaz and the Hospital Universitario 12 de Octubre. Early collaborators included the Universidad Complutense de Madrid, the Universidad de Barcelona, and the Consejo Superior de Investigaciones Científicas, while international engagement involved entities such as the World Health Organization, European Centre for Disease Prevention and Control, and the ClinicalTrials.gov registry. Milestones included harmonization with the Clinical Trial Regulation (EU) No 536/2014 and partnerships with the Horizon 2020 programme and the Innovative Medicines Initiative.
The governance structure ties to the Instituto de Salud Carlos III and interfaces with regional health ministries like the Junta de Andalucía and the Generalitat de Catalunya. Leadership interacts with advisory boards drawing expertise from universities such as the Universidad Autónoma de Madrid and the Universidad de Valencia and from hospitals including Hospital Universitario Ramón y Cajal and Hospital Universitario Gregorio Marañón. Regulatory oversight involves the Agencia Española de Protección de Datos for data governance, ethics committees akin to those at Hospital Universitario Vall d'Hebron, and collaboration with the European Medicines Agency and the Comisión Europea for cross-border trials. Strategic planning references frameworks used by the National Institutes of Health and the Cancer Research UK.
Programs encompass oncology trials linked with Centro Nacional de Investigaciones Oncológicas and personalized medicine projects involving genomic platforms at Barcelona Supercomputing Center and CNIO collaborators. Infectious disease trials have partnered with Hospital Clínic de Barcelona, Hospital Universitari Germans Trias i Pujol, and networks such as REMAP-CAP and Solidarity Trial structures, while cardiovascular studies engage centers like Hospital Universitario La Paz and research units influenced by European Society of Cardiology protocols. Pediatric research includes collaborations with Hospital Sant Joan de Déu and trial designs referencing International Council for Harmonisation standards. Trials have interfaced with pharmaceutical sponsors including Pfizer, AstraZeneca, Novartis, and device makers like Medtronic.
The network partners with Spanish institutions such as Fundación para la Investigación Biomédica Hospital 12 de Octubre, academic centers including the Universidad de Sevilla and Universidad de Granada, and international consortia such as EATRIS, ELIXIR, and the European Clinical Research Infrastructure Network. Industry collaborations include Johnson & Johnson and biotech firms like Grifols, while public–private engagements mirror models from National Institute for Health and Care Research and European Innovation Council initiatives. It also participates in pandemic response alliances with World Health Organization, European Centre for Disease Prevention and Control, and national public health bodies such as the Instituto de Salud Carlos III.
Primary funding streams originate from the Instituto de Salud Carlos III and Spanish ministry allocations processed through regional bodies like the Conselleria de Sanitat and the Consejería de Salud. Supplementary funding derives from EU programmes including Horizon Europe, philanthropic foundations such as the Fundación Ramón Areces and Fundación La Caixa, and industry-sponsored trial budgets from firms like Roche and Novartis. Budget oversight aligns with auditing practices used by the Court of Auditors (Spain) and financial regulations under the Ministerio de Hacienda.
The network leverages hospital research infrastructures at Hospital Clínic de Barcelona, Hospital Universitario Marqués de Valdecilla, and Hospital Universitario Virgen del Rocío, and biobanking resources such as those coordinated with Biobanco del Sistema Sanitario Público de Andalucía and the Spanish National Biobank Platform. Computational support integrates resources from Barcelona Supercomputing Center and data standards following FAIR data principles via partnerships with ELIXIR. Central laboratories collaborate with institutions like CNIO and Instituto de Salud Carlos III reference centers; imaging cores link to facilities at Hospital Universitario La Paz and Hospital Universitario 12 de Octubre.
The network has supported high-impact multicenter trials informing practices at Hospital Clínic de Barcelona, influenced national guidelines adopted by the Sociedad Española de Medicina Interna and Sociedad Española de Oncología Médica, and contributed data to EU initiatives such as Horizon 2020 projects and European Medicines Agency submissions. Notable outputs include collaborative studies with CNIO and Grifols on hematology, multicenter infectious disease trials aligned with WHO recommendations, and translational oncology programs linked to Vall d'Hebron Institute of Oncology and Centro Nacional de Investigaciones Oncológicas. The network’s role in pandemic-era trials paralleled efforts by RECOVERY Trial partners and supported national surveillance coordinated with Instituto de Salud Carlos III.
Category:Medical research in Spain